Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.49 |
| ▸ | CTSB | P07858 | 5/20 | 0.49 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16343329 | 1.00 | CTSL (0.49) | CTSLCTSBTACR1CTSSCTSK | |
| SCHEMBL16343328 | 1.00 | CTSL (0.49) | CTSLCTSBTACR1CTSSCTSK | |
| SCHEMBL15019911 | 0.91 | ITGB3 (0.48) | CTSLCTSBTACR1CTSSCTSK | |
| SCHEMBL15019914 | 0.91 | ITGB3 (0.48) | CTSLCTSBTACR1CTSSCTSK | |
| SCHEMBL16295347 | 0.90 | CAPN1 (0.55) | CTSLCTSBTACR1CTSSCTSK | |
| SCHEMBL30065143 | 0.86 | CTSL (0.62) | CTSLCTSBTACR1CTSSCTSK | |
| SCHEMBL30645061 | 0.85 | CTSL (0.61) | CTSLCTSBTACR1CTSSCTSK | |
| SCHEMBL16305637 | 0.84 | ITGB3 (0.50) | CTSLCTSSCTSKBCL2 | |
| SCHEMBL22167246 | 0.83 | ALDH1A1 (0.54) | CTSLCTSBTACR1CTSSCTSK | |
| SCHEMBL16294752 | 0.83 | ITGB3 (0.56) | CTSLCTSBTACR1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| US-9260427-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | CTSL 1635/4885CTSB 1692/4885TACR1 202/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | CTSL 1635/4885CTSB 1692/4885TACR1 202/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | CTSL 1620/4885CTSB 1992/4885TACR1 320/4885 |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | CTSL 1635/4885CTSB 1692/4885TACR1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.